Lapatinib vs Trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy: Primary efficacy endpoint
Comparing the prediction of chemotherapy benefit in patients with node-negative, ER-positive breast cancer using the recurrence
Adjuvant treatment with Zoledronic Acid in stage II/II breast cancer. The AZURE Trial (BIG 01/04). RE COLEMAN et al
Prospective Outcomes for Patients with Micro-Metastases and Macro-Metastases In Sentinel Nodes: NSABP B-32 Sentinel Node
Outcome according to CYP2D6 genotype among postmenopausal women with endocrine-responsive early invasive breast cancer randomized in the BIG 1-98 trial. B LEYLAND-JONES et al.
Final analysis of NCIC CTG MA.27: A randomized phase III trial of Exemestane versus Anastrozole in postmenopausal women with hormone receptor positive primary breast cancer. P GOSS et al.
A Genomic Predictor of Survival Following Taxane-Anthracycline Chemotherapy for Breast Cancer. WF SYMMANS et al
Identification of a clinically relevant gene signature in triple negative and basal like breast cancer. A RODY et al
